We investigated 88 AML patients with a median age of 61years and ( 1 ) cytogenetically normal AML ( CN-AML ) , ( 2 ) monoallelic ( moCEBPA ) or biallelic ( biCEBPA ) CEBPA mutation , and ( 3 ) intensive induction treatment .